NCT06622135

Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease

Development of a Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease Using Tasso Lancet Device

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Insight Research Institute · Academic / Other
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The goal of this is to develop an easy at home test that can be used to assist in diagnosing Alzheimer's disease (AD). The test will use an FDA approved device for at home blood sample collection. The blood samples will be evaluated to determine if the concentration of p-tau217, a biomarker that is elevated in AD patients, measured from blood samples collected using the at home device is comparable to the results obtained from blood samples collected by venipuncture.

Conditions

• Alzheimer Disease
• Healthy Subjects

Interventions

Type	Name	Description
DEVICE	Tasso Lancet Device	blood samples will be obtained from all participants using Tasso device

Timeline

• Start date: 2024-09-19
• Primary completion: 2024-12-07
• Completion: 2024-12-07
• First posted: 2024-10-01
• Last updated: 2025-02-11

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated device study